JP2016528198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528198A5 JP2016528198A5 JP2016524371A JP2016524371A JP2016528198A5 JP 2016528198 A5 JP2016528198 A5 JP 2016528198A5 JP 2016524371 A JP2016524371 A JP 2016524371A JP 2016524371 A JP2016524371 A JP 2016524371A JP 2016528198 A5 JP2016528198 A5 JP 2016528198A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- diabetes
- antibody fragment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842745P | 2013-07-03 | 2013-07-03 | |
| US61/842,745 | 2013-07-03 | ||
| US201461982611P | 2014-04-22 | 2014-04-22 | |
| US61/982,611 | 2014-04-22 | ||
| PCT/US2014/045389 WO2015003122A2 (en) | 2013-07-03 | 2014-07-03 | Regulation of glucose metabolism using anti-cgrp antibodies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018128766A Division JP2018168186A (ja) | 2013-07-03 | 2018-07-06 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
| JP2019052046A Division JP2019112455A (ja) | 2013-07-03 | 2019-03-20 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528198A JP2016528198A (ja) | 2016-09-15 |
| JP2016528198A5 true JP2016528198A5 (cg-RX-API-DMAC10.html) | 2017-08-10 |
| JP6502337B2 JP6502337B2 (ja) | 2019-04-17 |
Family
ID=52144290
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524371A Active JP6502337B2 (ja) | 2013-07-03 | 2014-07-03 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
| JP2018128766A Withdrawn JP2018168186A (ja) | 2013-07-03 | 2018-07-06 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
| JP2019052046A Pending JP2019112455A (ja) | 2013-07-03 | 2019-03-20 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
| JP2020104177A Pending JP2020158525A (ja) | 2013-07-03 | 2020-06-17 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018128766A Withdrawn JP2018168186A (ja) | 2013-07-03 | 2018-07-06 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
| JP2019052046A Pending JP2019112455A (ja) | 2013-07-03 | 2019-03-20 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
| JP2020104177A Pending JP2020158525A (ja) | 2013-07-03 | 2020-06-17 | 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整 |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150017166A1 (en) * | 2013-07-03 | 2015-01-15 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| EP4196611A1 (en) * | 2020-08-15 | 2023-06-21 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr) |
| CN117813325A (zh) | 2021-08-27 | 2024-04-02 | H.隆德贝克有限公司 | 使用抗cgrp抗体治疗丛集性头痛 |
| WO2025262247A1 (en) | 2024-06-21 | 2025-12-26 | H. Lundbeck A/S | Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| DE68924372T2 (de) * | 1988-01-11 | 1996-05-09 | Amylin Pharmaceuticals Inc | Behandlung von diabetes mellitus typ 2. |
| US5266561A (en) * | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| US5364841A (en) * | 1988-01-11 | 1994-11-15 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and essential hypertension and related disorders |
| US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE68923790T2 (de) * | 1989-01-03 | 1996-05-15 | Motorola Inc | Verfahren zum herstellen von löthöckern hoher dichte und ein substratsockel für löthöcker hoher dichte. |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| IE71195B1 (en) * | 1989-07-10 | 1997-02-12 | Amylin Corp | Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related disorders |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| EP1461068A4 (en) * | 2001-11-26 | 2006-03-29 | Protemix Corp Ltd | METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| SI3045182T1 (en) * | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| EP2021463B1 (en) | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
| NZ601583A (en) | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
| PT3495392T (pt) * | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| EA033109B1 (ru) * | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp |
| US20150017166A1 (en) * | 2013-07-03 | 2015-01-15 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
-
2014
- 2014-07-03 US US14/323,028 patent/US20150017166A1/en not_active Abandoned
- 2014-07-03 MX MX2016000220A patent/MX374612B/es active IP Right Grant
- 2014-07-03 WO PCT/US2014/045389 patent/WO2015003122A2/en not_active Ceased
- 2014-07-03 TW TW103122993A patent/TWI712419B/zh active
- 2014-07-03 EP EP14820173.4A patent/EP3016684B1/en active Active
- 2014-07-03 CA CA2916980A patent/CA2916980C/en active Active
- 2014-07-03 IL IL243355A patent/IL243355B2/en unknown
- 2014-07-03 AU AU2014285052A patent/AU2014285052B2/en active Active
- 2014-07-03 JP JP2016524371A patent/JP6502337B2/ja active Active
- 2014-07-03 KR KR1020167002907A patent/KR102476907B1/ko active Active
- 2014-07-03 SG SG11201510618YA patent/SG11201510618YA/en unknown
- 2014-07-03 CN CN201480047723.5A patent/CN105492026B/zh active Active
- 2014-07-03 SG SG10201906172XA patent/SG10201906172XA/en unknown
- 2014-07-03 ES ES14820173T patent/ES2911690T3/es active Active
- 2014-07-03 TW TW109121891A patent/TWI753471B/zh active
- 2014-07-03 NZ NZ754427A patent/NZ754427A/en unknown
-
2018
- 2018-07-06 JP JP2018128766A patent/JP2018168186A/ja not_active Withdrawn
-
2019
- 2019-03-20 JP JP2019052046A patent/JP2019112455A/ja active Pending
- 2019-12-10 AU AU2019279945A patent/AU2019279945B2/en active Active
-
2020
- 2020-06-17 JP JP2020104177A patent/JP2020158525A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7642588B2 (ja) | 療法のためｇｉｐ／ｇｌｐ１コアゴニストを使用する方法 | |
| Bhattamisra et al. | Type-3c diabetes mellitus, diabetes of exocrine pancreas-an update | |
| TWI772250B (zh) | IL-22多肽及IL-22Fc融合蛋白質及其使用方法 | |
| Suzuki et al. | Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 receptors | |
| TW202323296A (zh) | 組合療法 | |
| KR20070090036A (ko) | Ｇｌｐ-1 작용제, 조성물, 방법 및 용도 | |
| JP2021502389A (ja) | 手術前、手術中または手術後に投与するためのｇｌｐ−２類似体及びｇｌｐ−２ペプチボディ | |
| TW201623330A (zh) | Ｉｌ－２１抗體 | |
| RS62627B1 (sr) | Tretman post-bariatrijske hipoglikemije sa glp-1 antagonistima | |
| KR20180096733A (ko) | 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제 | |
| JP2020521765A (ja) | 慢性腎疾患の治療のためのデュラグルチド | |
| US20220315633A1 (en) | Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake | |
| CN102834413A (zh) | 代谢障碍的治疗 | |
| CN102548573A (zh) | Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途 | |
| IL323508A (en) | Methods and uses for treating nausea and vomiting | |
| CN116920100A (zh) | 一种治疗肿瘤的药物组合物及其应用 | |
| HK40128497A (zh) | 使用gip/glp1共激动剂用於治疗的方法 | |
| Kakati et al. | Beta Cell Preservation | |
| JP2017081910A (ja) | 血糖恒常性を維持するための医薬組成物 | |
| EP1871811A2 (en) | Human glp-1 mimetibodies, compositions, methods and uses | |
| CN103007254A (zh) | 胰高血糖素样肽-1在制备1型糖尿病药物中的应用 | |
| JP2023505126A (ja) | 肥満症の処置のためのグルカゴン及びｇｌｐ－１のコアゴニストを使用する組合せ治療 |